Views & Analysis | Perspectives on pharma industry issues

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

From phase 1 to phase 3: Scaling radiopharmaceutical trials

Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

R&D

Gravity is an experimental variable pharma has rarely been a...

Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.

Articles

Expert review: ABPI Code 2011 update – implementation and im...

In the second part of our Expert Review series, Dr Rob Barden offers his expert opinion on the 2011 changes to the ABPI code and what they will really mean for the industry. January 2011 saw the introduction of the updated ABPI Code of Practice, with initial implementation being completed by the end of April. So what were...

Articles

Expert review: doing business in the Nordics

With the Nordics representing a significant business opportunity for many pharma companies, Frode Hellesnes offers some pearls of wisdom for those contemplating entering the Nordic markets. Some 24.5 million inhabitants are living in the four main countries in the Nordics: Denmark, Finland, Norway and Sweden. If one also includes...

Articles

When you are engulfed in flames: the dangers of Value Based ...

Rob Walton highlights the dangers associated with value based pricing to pharma in the UK. We’ve heard a lot this year about fire as a catalyst for radical action. It started, back in February when Nokia CEO, Stephen Elop, sent a memo to his...

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.